Rhythm Pharmaceuticals, Inc.(RYTM)Earnings, Financials & Key RatiosRhythm Pharmaceuticals, Inc. (RYTM) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's precarious liquidity position, highlighted by a $54.3 million cash balance against a TTM net loss exceeding $190 million, suggests that significant financing risks remain for shareholders.
Rhythm Pharmaceuticals, Inc. (RYTM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Rhythm Pharmaceuticals, Inc. (RYTM) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.83vs $0.86+3.5% | $60Mvs $56M+7.8% |
| Q1 2026 | Feb 26, 2026 | $0.73vs $0.79+7.6% | $57Mvs $56M+1.9% |
| Q4 2025 | Nov 4, 2025 | $0.82vs $0.72-13.9% | $51Mvs $56M-8.4% |
| Q3 2025 | Aug 5, 2025 | $0.75vs $0.66-13.6% | $49Mvs $51M-5.5% |
Recent stock market news and headlines for Rhythm Pharmaceuticals, Inc. (RYTM)
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ: RGPX) reported that setmelanotide therapy produced robust, sustained and clinically significant weight loss in patients with acquired hypothalamic obesity at 2.5 years. Alongside the long-term setmelanotide results, Rhythm reported that bivamelagon therapy achieved progressive reductions in body mass index and hunger measures in patients with acquired hypothalamic obesity at one year.
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced new data from multiple presentations during the Endocrine Society's Annual Meeting (ENDO 2026) in Chicago.
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) stock is trading higher on Monday after the company reported preliminary results from an ongoing Phase 2 study evaluating setmelanotide in patients with Prader-Willi syndrome (PWS).
Key metrics vs top competitors for Rhythm Pharmaceuticals, Inc. (RYTM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $114.46 | $7.84B | -36.80 | 45.83% | -103.57% | -129.46% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $94.66 | $6.27B | 69.09 | 15.24% | 9.48% | 5.13% | — | |
| $89.20 | $7.4B | 11.47 | 114.51% | -22.58% | — | — |
Rhythm Pharmaceuticals, Inc. (RYTM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Rhythm Pharmaceuticals, Inc. (RYTM) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Apr 3, 2026·SEC
Mar 26, 2026·SEC
Get notified when RYTM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Rhythm Pharmaceuticals, Inc. (RYTM) stock FAQ — growth, dividends, profitability & financials explained
Rhythm Pharmaceuticals, Inc. (RYTM) reported $217.2M in revenue for fiscal year 2025.
Rhythm Pharmaceuticals, Inc. (RYTM) grew revenue by 45.8% over the past year. This is strong growth.
Rhythm Pharmaceuticals, Inc. (RYTM) reported a net loss of $203.8M for fiscal year 2025.
Rhythm Pharmaceuticals, Inc. (RYTM) has a return on equity (ROE) of -129.5%. Negative ROE indicates the company is unprofitable.
Rhythm Pharmaceuticals, Inc. (RYTM) had negative free cash flow of $76.3M in fiscal year 2025, likely due to heavy capital investments.
